These results suggest that targeting cathepsin L–mediated GCase degradation represents a potential therapeutic strategy for GCase deficiency in PD and related disorders that exhibit decreased GCase activity. The gene discussed is CTSL; the disease is hyperinsulinemic hypoglycemia, familial, 4.